•The PanOptix trifocal IOL utilizes a unique hybrid central non-apodized diffractive and peripheral refractive design with Enhanced Light Energy (ENLIGTHEN) technology to
- Provide focal points at far distance, patient comfortable intermediate at 60 cm and near at 40 cm1,2
- Provide 88% light utilization with less dependence on pupil size
• The global pooled analysis shows bilateral implantation of the PanOptix IOL provides a continuous range of vision of 0.1 logMAR (Snellen 20/25) or better vision from distance to near at 33 cm, with low incidences of ocular adverse device effects and secondary surgical interventions3
• Meta-analysis shows 92% cataract patients have complete spectacle independence4 and less than 3% cataract patients will experience very bothersome visual phenomena5 after bilateral implantation of the PanOptix IOLs
• The PanOptix IOL provides a similar range of vision from distance to near at 33 cm in both photopic and mesopic conditions, with a better visual disturbance profile compared to Synergy IOL6,7
• Implantation of PanOptix is a cost-beneficial treatment strategy to provide greater improvement in vision related quality of life compared to a monofocal IOL.